Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites

Table 4 Immune related adverse events, n (%)

	All (n = 124)		HAB (n = 26)		LAB (n = 98)		P value
	All	Grade 3 or more	All	Grade 3 or more	All	Grade 3 or more	All	Grade 3 or more
Any adverse event	45 (36)	12 (10)	6 (23)	2 (8)	39 (40)	10 (10)	0.168	1.000
Skin reaction	16 (13)	0	0	0	16 (16)	0	0.023	-
Hypothyroidism	7 (6)	0	1 (4)	0	6 (6)	0	1.000	-
Adrenal insufficiency	5 (4)	2 (2)	0	0	5 (5)	2 (2)	0.583	1.000
Hypopituitary function	2 (2)	0	0	0	2 (2)	0	1.000	-
Pneumonitis	9 (7)	3 (2)	4 (15)	1 (4)	5 (5)	2 (2)	0.091	0.510
Colitis	6 (5)	2 (2)	0	0	6 (6)	2 (2)	0.342	0.579
Hepatitis	2 (2)	2 (2)	0	0	2 (2)	2 (2)	1.000	1.000
Nephritis	2 (2)	1 (1)	1 (4)	0	1 (1)	1 (1)	0.377	1.000
Myositis	1 (1)	1 (1)	0	0	1 (1)	1 (1)	1.000	1.000
Polymyalgia	1 (1)	0	0	0	1 (1)	0	1.000	-
Arthritis	1 (1)	0	0	0	1 (1)	0	1.000	-
Cholangitis	1 (1)	1 (1)	1 (4)	1 (4)	0	0	1.000	1.000

HAB: High ascites burden; LAB: Low ascites burden.